A cohort-based multi-omics identifies nuclear translocation of eIF5B /PD-L1/CD44 complex as the target to overcome Osimertinib resistance of ARID1A-deficient lung adenocarcinoma
Abstract Background Osimertinib has emerged as a critical element in the treatment landscape following recent clinical trials. Further investigation into the mechanisms driving resistance to Osimertinib is necessary to address the restricted treatment options and survival advantages that are comprom...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Experimental Hematology & Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40164-024-00594-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544937622994944 |
|---|---|
| author | Dantong Sun Helei Hou Feiyue Feng Weizheng Wu Jingyu Tan Tongji Xie Jiayu Liu Jinsong Wang Haili Qian Junling Li Puyuan Xing |
| author_facet | Dantong Sun Helei Hou Feiyue Feng Weizheng Wu Jingyu Tan Tongji Xie Jiayu Liu Jinsong Wang Haili Qian Junling Li Puyuan Xing |
| author_sort | Dantong Sun |
| collection | DOAJ |
| description | Abstract Background Osimertinib has emerged as a critical element in the treatment landscape following recent clinical trials. Further investigation into the mechanisms driving resistance to Osimertinib is necessary to address the restricted treatment options and survival advantages that are compromised by resistance in patients with EGFR-mutated lung adenocarcinoma (LUAD). Methods Spatial transcriptomic and proteomic analyses were utilized to investigate the mechanisms of Osimertinib resistance. Co-IP, MS, RNA-seq, ChIP-seq, RIP-seq, and ATAC-seq were performed in cell lines to further explore the mechanism. To validate the findings, in vitro and in vivo molecular experiments were conducted. Results We found that the ARID1A deficiency results in resistance to Osimertinib by hindering programmed cell death through the EZH2/PTEN/E2F1 axis. This altered axis influences PD-L1 transcription through E2F1-mediated promoter activation and PD-L1 translation via the MDM2/eIF5B/PD-L1 axis. Subsequently, ARID1A deficiency results in increased expression of eIF5B and Importin-β1, promoting PD-L1 nuclear-translocation. The nuclear PD-L1 (nPD-L1) interacts with CD44, leading to nPD-L1 complex formation, activation of the RASGEF1A promoter, initiation of the Ras pathway, and contributing to Osimertinib resistance. Targeting the transcription, translation and nuclear-translocation of PD-L1 using lipid nanoparticles (LNPs) overcomes ARID1A deficiency-induced resistance. Conclusion ARID1A deficiency promotes PD-L1 nuclear translocation and induces Osimertinib resistance. |
| format | Article |
| id | doaj-art-c86c1f2c9fd44b32b3012064fb7ac805 |
| institution | Kabale University |
| issn | 2162-3619 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Experimental Hematology & Oncology |
| spelling | doaj-art-c86c1f2c9fd44b32b3012064fb7ac8052025-01-12T12:11:05ZengBMCExperimental Hematology & Oncology2162-36192025-01-0114111910.1186/s40164-024-00594-4A cohort-based multi-omics identifies nuclear translocation of eIF5B /PD-L1/CD44 complex as the target to overcome Osimertinib resistance of ARID1A-deficient lung adenocarcinomaDantong Sun0Helei Hou1Feiyue Feng2Weizheng Wu3Jingyu Tan4Tongji Xie5Jiayu Liu6Jinsong Wang7Haili Qian8Junling Li9Puyuan Xing10Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Oncology, The Affiliated Hospital of Qingdao UniversityDepartment of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeState Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeAbstract Background Osimertinib has emerged as a critical element in the treatment landscape following recent clinical trials. Further investigation into the mechanisms driving resistance to Osimertinib is necessary to address the restricted treatment options and survival advantages that are compromised by resistance in patients with EGFR-mutated lung adenocarcinoma (LUAD). Methods Spatial transcriptomic and proteomic analyses were utilized to investigate the mechanisms of Osimertinib resistance. Co-IP, MS, RNA-seq, ChIP-seq, RIP-seq, and ATAC-seq were performed in cell lines to further explore the mechanism. To validate the findings, in vitro and in vivo molecular experiments were conducted. Results We found that the ARID1A deficiency results in resistance to Osimertinib by hindering programmed cell death through the EZH2/PTEN/E2F1 axis. This altered axis influences PD-L1 transcription through E2F1-mediated promoter activation and PD-L1 translation via the MDM2/eIF5B/PD-L1 axis. Subsequently, ARID1A deficiency results in increased expression of eIF5B and Importin-β1, promoting PD-L1 nuclear-translocation. The nuclear PD-L1 (nPD-L1) interacts with CD44, leading to nPD-L1 complex formation, activation of the RASGEF1A promoter, initiation of the Ras pathway, and contributing to Osimertinib resistance. Targeting the transcription, translation and nuclear-translocation of PD-L1 using lipid nanoparticles (LNPs) overcomes ARID1A deficiency-induced resistance. Conclusion ARID1A deficiency promotes PD-L1 nuclear translocation and induces Osimertinib resistance.https://doi.org/10.1186/s40164-024-00594-4ARID1ANuclear eIF5B/PD-L1/CD44 complexRas pathwayOsimertinibLung adenocarcinoma |
| spellingShingle | Dantong Sun Helei Hou Feiyue Feng Weizheng Wu Jingyu Tan Tongji Xie Jiayu Liu Jinsong Wang Haili Qian Junling Li Puyuan Xing A cohort-based multi-omics identifies nuclear translocation of eIF5B /PD-L1/CD44 complex as the target to overcome Osimertinib resistance of ARID1A-deficient lung adenocarcinoma Experimental Hematology & Oncology ARID1A Nuclear eIF5B/PD-L1/CD44 complex Ras pathway Osimertinib Lung adenocarcinoma |
| title | A cohort-based multi-omics identifies nuclear translocation of eIF5B /PD-L1/CD44 complex as the target to overcome Osimertinib resistance of ARID1A-deficient lung adenocarcinoma |
| title_full | A cohort-based multi-omics identifies nuclear translocation of eIF5B /PD-L1/CD44 complex as the target to overcome Osimertinib resistance of ARID1A-deficient lung adenocarcinoma |
| title_fullStr | A cohort-based multi-omics identifies nuclear translocation of eIF5B /PD-L1/CD44 complex as the target to overcome Osimertinib resistance of ARID1A-deficient lung adenocarcinoma |
| title_full_unstemmed | A cohort-based multi-omics identifies nuclear translocation of eIF5B /PD-L1/CD44 complex as the target to overcome Osimertinib resistance of ARID1A-deficient lung adenocarcinoma |
| title_short | A cohort-based multi-omics identifies nuclear translocation of eIF5B /PD-L1/CD44 complex as the target to overcome Osimertinib resistance of ARID1A-deficient lung adenocarcinoma |
| title_sort | cohort based multi omics identifies nuclear translocation of eif5b pd l1 cd44 complex as the target to overcome osimertinib resistance of arid1a deficient lung adenocarcinoma |
| topic | ARID1A Nuclear eIF5B/PD-L1/CD44 complex Ras pathway Osimertinib Lung adenocarcinoma |
| url | https://doi.org/10.1186/s40164-024-00594-4 |
| work_keys_str_mv | AT dantongsun acohortbasedmultiomicsidentifiesnucleartranslocationofeif5bpdl1cd44complexasthetargettoovercomeosimertinibresistanceofarid1adeficientlungadenocarcinoma AT heleihou acohortbasedmultiomicsidentifiesnucleartranslocationofeif5bpdl1cd44complexasthetargettoovercomeosimertinibresistanceofarid1adeficientlungadenocarcinoma AT feiyuefeng acohortbasedmultiomicsidentifiesnucleartranslocationofeif5bpdl1cd44complexasthetargettoovercomeosimertinibresistanceofarid1adeficientlungadenocarcinoma AT weizhengwu acohortbasedmultiomicsidentifiesnucleartranslocationofeif5bpdl1cd44complexasthetargettoovercomeosimertinibresistanceofarid1adeficientlungadenocarcinoma AT jingyutan acohortbasedmultiomicsidentifiesnucleartranslocationofeif5bpdl1cd44complexasthetargettoovercomeosimertinibresistanceofarid1adeficientlungadenocarcinoma AT tongjixie acohortbasedmultiomicsidentifiesnucleartranslocationofeif5bpdl1cd44complexasthetargettoovercomeosimertinibresistanceofarid1adeficientlungadenocarcinoma AT jiayuliu acohortbasedmultiomicsidentifiesnucleartranslocationofeif5bpdl1cd44complexasthetargettoovercomeosimertinibresistanceofarid1adeficientlungadenocarcinoma AT jinsongwang acohortbasedmultiomicsidentifiesnucleartranslocationofeif5bpdl1cd44complexasthetargettoovercomeosimertinibresistanceofarid1adeficientlungadenocarcinoma AT hailiqian acohortbasedmultiomicsidentifiesnucleartranslocationofeif5bpdl1cd44complexasthetargettoovercomeosimertinibresistanceofarid1adeficientlungadenocarcinoma AT junlingli acohortbasedmultiomicsidentifiesnucleartranslocationofeif5bpdl1cd44complexasthetargettoovercomeosimertinibresistanceofarid1adeficientlungadenocarcinoma AT puyuanxing acohortbasedmultiomicsidentifiesnucleartranslocationofeif5bpdl1cd44complexasthetargettoovercomeosimertinibresistanceofarid1adeficientlungadenocarcinoma AT dantongsun cohortbasedmultiomicsidentifiesnucleartranslocationofeif5bpdl1cd44complexasthetargettoovercomeosimertinibresistanceofarid1adeficientlungadenocarcinoma AT heleihou cohortbasedmultiomicsidentifiesnucleartranslocationofeif5bpdl1cd44complexasthetargettoovercomeosimertinibresistanceofarid1adeficientlungadenocarcinoma AT feiyuefeng cohortbasedmultiomicsidentifiesnucleartranslocationofeif5bpdl1cd44complexasthetargettoovercomeosimertinibresistanceofarid1adeficientlungadenocarcinoma AT weizhengwu cohortbasedmultiomicsidentifiesnucleartranslocationofeif5bpdl1cd44complexasthetargettoovercomeosimertinibresistanceofarid1adeficientlungadenocarcinoma AT jingyutan cohortbasedmultiomicsidentifiesnucleartranslocationofeif5bpdl1cd44complexasthetargettoovercomeosimertinibresistanceofarid1adeficientlungadenocarcinoma AT tongjixie cohortbasedmultiomicsidentifiesnucleartranslocationofeif5bpdl1cd44complexasthetargettoovercomeosimertinibresistanceofarid1adeficientlungadenocarcinoma AT jiayuliu cohortbasedmultiomicsidentifiesnucleartranslocationofeif5bpdl1cd44complexasthetargettoovercomeosimertinibresistanceofarid1adeficientlungadenocarcinoma AT jinsongwang cohortbasedmultiomicsidentifiesnucleartranslocationofeif5bpdl1cd44complexasthetargettoovercomeosimertinibresistanceofarid1adeficientlungadenocarcinoma AT hailiqian cohortbasedmultiomicsidentifiesnucleartranslocationofeif5bpdl1cd44complexasthetargettoovercomeosimertinibresistanceofarid1adeficientlungadenocarcinoma AT junlingli cohortbasedmultiomicsidentifiesnucleartranslocationofeif5bpdl1cd44complexasthetargettoovercomeosimertinibresistanceofarid1adeficientlungadenocarcinoma AT puyuanxing cohortbasedmultiomicsidentifiesnucleartranslocationofeif5bpdl1cd44complexasthetargettoovercomeosimertinibresistanceofarid1adeficientlungadenocarcinoma |